Table 2.

The interobserver agreement among pathologists before and after p53 immunohistochemistry (stages I and II assessment)

The interobserver agreement (κ)	Stage I assessment (H&E)	Stage II assessment (H&E + p53‐IHC)
Overall	0.23 (95% CI = 0.12 to 0.34)	0.39 (95% CI = 0.30 to 0.50)
NDBE	0.31 (95% CI = 0.19 to 0.44)	0.46 (95% CI = 0.32 to 0.58)
BE‐IND	0.21 (95% CI = 0.07 to 0.34)	0.26 (95% CI = 0.09 to 0.43)
LGD	−0.03 (95%CI = –0.50 to 0.43)	0.49 (95% CI = 0.26 to 0.73)
HGD/IMC	−0.02 (95%CI = –0.64 to 0.60)	0.35 (95% CI = –0.13 to 0.83)
All dysplasia	0.17 (95% CI = –0.17 to 0.51)	0.44 (95% CI = 0.22 to 0.66)

BE‐IND, Barrett's oesophagus indefinite for dysplasia; H&E, haematoxylin and eosin (staining); HGD/IMC, high‐grade dysplasia/intramucosal cancer; LGD, low‐grade dysplasia; NDBE, non‐dysplastic Barrett's oesophagus; P53‐IHC, P53 immunohistochemistry.